Lan Chao, Lyu Qing, Pei Hui, Meng Xing, Liu Qi, Jia Xinya, Li Zhongshi, Wang Chao, Ye Huaqing, Fan Yijun
Department of Emergency Intensive Care Unit, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, Henan, China. Corresponding author: Lan Chao, Email:
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018 Aug;30(8):783-789. doi: 10.3760/cma.j.issn.2095-4352.2018.08.014.
To comprehensively evaluate the clinical efficacy of hemoperfusion (HP) combined with continuous veno-venous hemofiltration (CVVH) on acute paraquat poisoning (APP).
Literatures of Chinese and English randomized controlled trials (RCTs), case control and cohort study on HP combined with CVVH in the treatment of APP from the PubMed, Embase, Wanfang, and CNKI up to November 2017 were enrolled (the subjects were > 16 years old). The obtained literatures were strictly screened and evaluated in quality, and data such as mortality, the life time of dead patients, inefficiency rate, incidence of multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS) were extracted. Meta-analysis was performed by RevMan 5.3.
Twenty-one studies were included with 2 222 subjects, among whom 976 subjects were in HP combined with CVVH group (experimental group) and 1 246 subjects in HP group (control group). Compared with control group, the mortality in experimental group were significantly decreased [43.77% (362/827) vs. 55.26% (604/1 093), odds ratio (OR) = 0.68, 95% confidential interval (95%CI) = 0.56-0.82, P = 0.000 1], the life time of death patients was significantly prolonged [mean difference (MD) = 4.63, 95%CI = 2.60-6.66, P < 0.000 01], incidence of MODS [25.93% (70/270) vs. 55.36% (155/280), OR = 0.26, 95%CI = 0.14-0.49, P < 0.000 1], and incidence of ARDS [30.37% (82/270) vs. 51.07% (143/280), OR = 0.42, 95%CI = 0.30-0.61, P < 0.000 01], and inefficiency rate [8.72% (13/149) vs. 34.64% (53/153), OR = 0.17, 95%CI = 0.09-0.34, P < 0.000 01] were significantly reduced. Funnel chart showed that except the publication bias of mortality rate, there were less publication bias about other indicators among studies.
HP combined with CVVH can significantly reduce the mortality of patients with APP compared with HP alone on the whole, prolong the life time and reduce the occurrence of MODS and ARDS, thus improving the treatment efficiency.
全面评估血液灌流(HP)联合连续性静脉-静脉血液滤过(CVVH)治疗急性百草枯中毒(APP)的临床疗效。
纳入截至2017年11月在PubMed、Embase、万方和知网中检索到的关于HP联合CVVH治疗APP的中英文随机对照试验(RCT)、病例对照及队列研究(研究对象年龄>16岁)。对获取的文献进行严格筛选和质量评价,提取死亡率、死亡患者生存时间、无效率、多器官功能障碍综合征(MODS)及急性呼吸窘迫综合征(ARDS)发生率等数据。采用RevMan 5.3软件进行Meta分析。
共纳入21项研究,2222例研究对象,其中HP联合CVVH组(试验组)976例,HP组(对照组)1246例。与对照组比较,试验组死亡率显著降低[43.77%(362/827)比55.26%(604/1093),比值比(OR)=0.68,95%置信区间(95%CI)=0.56-0.82,P=0.0001],死亡患者生存时间显著延长[平均差(MD)=4.63,95%CI=2.60-6.66,P<0.00001],MODS发生率[25.93%(70/270)比55.36%(155/280),OR=0.26,95%CI=0.14-0.49,P<0.0001]、ARDS发生率[30.37%(82/270)比51.07%(143/280),OR=0.42,95%CI=0.30-0.61,P<0.00001]及无效率[8.72%(13/149)比34.64%(53/153),OR=0.17,95%CI=0.09-0.34,P<0.00001]均显著降低。漏斗图显示,除死亡率存在发表偏倚外,其他指标研究间发表偏倚较小。
总体而言,HP联合CVVH较单独HP能显著降低APP患者死亡率,延长生存时间,减少MODS和ARDS的发生,从而提高治疗效果。